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The tumor proliferation index marker Ki-67 is strongly associated with tumor cell prolifera-
tion, growth and progression, and is widely used in routine clinicopathological investigation.
Prostate cancer is a complex multifaceted and biologically heterogeneous disease, and
overtreatment of localized, low volume indolent tumors, is evident. Here, we aimed to
assess Ki-67 expression and related outcomes of 535 patients treated with radical prosta-
tectomy. The percentage of tumor epithelial cells expressing Ki-67 was determined by
immunohistochemical assay, both digital image analysis and visual scoring by light micro-
scope were used for quantification. The association of Ki-67 and prostate cancer was
evaluated, as well as its prognostic value. There was a positive correlation between high
expression of Ki-67 and Gleason score > 7 (p < 0.001) as well as tumor size ( 20 mm,
p = 0.03). In univariate analyses, a high expression of Ki-67 in tumor epithelium was signifi-
cantly associated with biochemical failure (BF) (digital scoring, p = 0.014) and (visual scor-
ing, p = 0.004). In the multivariate analyses, a high level of Ki-67 was an independent poor
prognostic factor for biochemical failure-free survival (BFFS) (Visual scoring, Ki67, p =
0.012, HR:1.50, CI95% 1.10–2.06). In conclusion, high Ki-67 expression is an independent
negative prognostic marker for biochemical failure. Our findings support the role of Ki-67 as
a significant, poor prognostic factor for in prostate cancer outcome.
Introduction
Radical prostatectomy as a primary treatment for clinically localized prostate cancer (PC) has
increased dramatically over the past decade due to prostate specific antigen (PSA) screening
[1]. Despite increased ability to detect cancer, the clinical behavior of PC remains hard to pre-
dict as it ranges from indolent to highly aggressive tumors [2]. Therefore, new prognostic bio-
markers are urgently needed. Management of PC today relies largely on standard clinical
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factors including Gleason score, prostate specific antigen (PSA) level, clinical stage and mea-
sures of tumor extent on biopsy and imaging. These methods, however, have a rather limited
potential to stratify indolent from aggressive disease [2–3]. After localized radical prostatec-
tomy and radiation therapy, 20–40% of the patients will relapse, progress, and will be in need
of androgen deprivation therapies [4].
The proliferation marker Ki-67 reflects the tumor cell proliferation rate as it correlates with
progression, metastasis and prognosis in a number of different malignancies [5–9]. Ki-67 is a
nuclear cell cycle-associated regulatory protein and the expression of it can be detected during
the interphase in the nucleus of tumor epithelial cells [10]. The fact that Ki-67 is involved dur-
ing all active phases of the cell cycle (G1, S, G2 and mitosis), and absent in resting cells (G0
phase), has made it an excellent marker for determining tumor growth fraction [11]. The Ki-
67 (MIB-1 antibody) labeling index is the best studied PC marker in needle-biopsies up to date
[12–17]. Several have found that Ki-67 labeling index shows strong correlation with Gleason
score in diagnostic biopsies [12, 14], in subsequent radical prostatectomy [15–17], or both
[13]. Others have found Ki-67 to be a biomarker for disease-free survival [13], seminal vesicle
invasion and postoperative biochemical recurrence [17], and cancer specific death after radical
prostatectomy [18]. Others have not been able to confirm these results [16].
The prognostic value of Ki-67 in PC remains somewhat contradictory and inconclusive
mainly due to the biologic tumor heterogeneity, lack of standardization in the immunohisto-
chemical (IHC) assays, quantification methods, cutoff-points used for risk classification, and
intra- and inter-observer variability.
The objective of this large multicenter study with long follow-up was to investigate if Ki-67
may provide additional information to prognostic indicators in PC. A cohort of 535 PC
patients, treated with radical prostatectomies but without pre-operative hormonal therapy was
investigated.
Materials and methods
Patients and tissue microarray
671 patients with radical prostatectomies (RPs) diagnosed with adenocarcinoma of the pros-
tate were retrospectively identified. The samples were collected between 01.01.1995 to
31.12.2005 from the archives of the Departments of Clinical Pathology at the University Hospi-
tal of North Norway, St. Olav Hospital and Nordland Hospital. Of these, 136 patients were
excluded due to other cancer within five years of PC diagnosis, radiotherapy to the pelvis prior
to surgery, inadequate paraffin-embedded tissue blocks and missing follow-up data. None of
the patients received a preoperative hormonal therapy. Included in the study was a total of 535
patients with complete follow-up data and available PC tissue. Median follow-up was 12.4
years (range 1.5–20 years). The most recent follow-up was December 2015. Biochemical failure
(BF) was defined as postoperative PSA 0.4ng/ml and rising in a minimum of two different
blood samples. Biochemical failure-free survival (BFFS) was calculated as time from surgery to
last follow up (FU) date, or date with PSA above threshold ( 0.4 ng/ml in a minimum of two
different blood samples postoperatively). Clinical failure-free survival (CFFS) was defined as
verified, symptomatic, locally advanced progression after radical treatments or metastasis to
bone, visceral organs or lymph nodes verified by radiology. Prostate cancer death free survival
(PCDFS), was defined as death caused by PC stated in the patient’s journal. Further informa-
tion regarding patients’ data, exclusion criteria, definitions of variables and endpoints, has
been previously published [19]. All primary cancers were histologically reviewed by two
pathologists (ER and LTB) and the tumors were graded according to the recent Gleason grad-
ing system; The 2014 International Society of Urological Pathology (ISUP) Consensus Conference
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on Gleason Grading of Prostatic Carcinoma [20] and staged according to the new guidelines
[21].
The current study was approved by the ethics committee, REK Nord (2009/1393), including
a mandatory re-application January 22. 2016, and the Data Protection Official for Research.
The National Data Inspection Board have approved the study. The ethics committee waived
the need for patients consent in this retrospective study. The patient records were anonymized
prior the research. The reporting of clinicopathological variables, survival data and biomarker
expressions was conducted in accordance with the REMARK guidelines [22].
Microarray construction
We used tissue microarrays (TMA) and twelve TMA blocks were constructed. A tissue-array-
ing instrument (Beecher Instruments, Silver Springs, MD, USA) was used for this purpose. We
collected formalin-fixed paraffin-embedded (FFPE) tissue blocks from included patients. The
author (ER) identified two different areas of tumor compartment (tumor epithelial cells) and
two areas of tumor surrounding microenvironment. Two areas of normal epithelial cells and
normal stromal tissue was also sampled as controls. Cores with a diameter of 0.6 mm from
donor block was collected and inserted into recipient TMA blocks. Multiple 4 μm sections
were cut with a Micron microtome (HM355S), affixed to glass slides, and sealed with paraffin.
The detailed methodology has been reported previously [23].
Immunohistochemistry (IHC) and quantification of Ki67 immunostaining
The following antibody from Ventana Medical Systems (Tucson, Arizona, USA) was applied
to assess the proliferative activity of normal and neoplastic tissues: CONFIRM Ki-67 (clone,
30–9), a rabbit monoclonal primary antibody directed against the C-terminal portion of the
Ki-67 antigen. The applied antibody is used in routine diagnostic IHC and has FDA approval
(510k) for IVD (in vitro diagnostic) use. Ki-67 positive staining was identified by the presence
of brown nuclear (DAB) staining in tumor cells. Ki-67 index was quantified using The ARIOL
imaging system (Applied Imaging Corp., San Jose, CA, USA) and light microscope. The
ARIOL imaging system consisted of a microscope (Olympus BX 61), an automatic stage, slide
loader and a camera. All cores were photographed at 20x magnification and the images was
semi-quantitatively scored. For both methods, the ARIOL imaging system and the light micro-
scope, the percentage of positive nuclear stained tumor cells among total number of at least
200 tumor cells were counted for each core and scored according to the following system:
0 = 0%, 1 = 1–2.5%, 2 = 2.6–4, 3 5%. For both methods, the scoring values were then dichot-
omized as high or low expression separated by mean value. A high expression was defined as
scoring values 1.43 (visual scoring using light microscope) and 1.34 (digital scoring).
Statistical methods
All statistical analyses were performed using the statistical package IBM SPSS, version 24
(SPSS Inc., Chicago, IL, USA). Spearman correlation coefficient was used to examine the asso-
ciation between Ki-67 score and clinicopathological variables. The Kaplan-Meier method was
used for the univariate survival analysis, and log-rank test was used to assess statistical signifi-
cance. Univariate analyses were performed for the following end-points: biochemical failure
(BF), clinical failure (CF) and death of prostate cancer (PCD). All significant variables from
the univariate analyses were entered into the multivariate model using backward stepwise Cox
regression model with a probability for stepwise entry and removal at 0.05 and 0.1, respec-
tively. The IHC scoring values from each pathologist were compared for inter-observer
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reliability by use of a two-way random effect model with absolute agreement definition. The
significance level used was p< 0.05 for all analyses.
Results
Patient characteristics
Overview of the patient’s characteristics’ is presented in Table 1 and S1 Table. Median age at
surgery was 62 years (47 to 76). The surgical procedures were retropubic in 435 cases (81%)
and perineal in 100 cases (19%). Gleason grade group ranged from 1 to 5 (updated Gleason
grade system); 1 ( 6), 2 (3+4), 3 (4+3), 4 (4+4) and 5 ( 8). Tumor stage ranged from T2a to
T3b. Median PSA was 8.8 (range 0.7–104). At the last follow-up, 200 (37%) had BF, 56 (11%)
had experienced CF and 18 (3.4%) had died of PC.
Ki67 expression and correlations with clinicopathological variables
Nuclear staining of Ki-67 in tumor epithelial cells was observed. The intensity of the nuclear
staining was varying from negative, weak, to moderate and strong, and all grades, except nega-
tive results, were regarded as positive cells (Fig 1). Ki-67 nuclear staining was evaluated by
using light microscope (visual scoring) and digital image analysis. Two experienced patholo-
gists independently scored the TMA-slides without any prior knowledge of the patients’ clini-
copathological data or any clinical end-points. Positive Ki-67 staining was clearly detected in
the nucleus of tumor epithelial cells, in 452 (84%) of the total of 535 patients (visual scoring)
and in 483 (90%), digital scoring method. Of those with detected staining, 61% had a low Ki-
67 expression (< 1.43) and 39% had a high expression ( 1.43). Using cutoff-value < 1.34
and 1.34, 60% had low expression and 40% a high expression, respectively (Fig 1A–1F).
Interobserver scoring agreement (ICC), for Ki-67 expression in tumor epithelial cells was:
ICC = 0.78 (CI: 0.74–0.82, p< 0.001). When stratifying the analyses by the different surgical
centres, the results remained unchanged. (S1 Fig)
The correlation between Ki-67 level and clinicopathological variables was generally weak or
non-significant (r< 0.2). However, positive correlations were found between high Ki-67
expression and Gleason grade8 (p = 0.001), tumor size 20 millimeter (p = 0.03) and
pT-Stage T3b (p = 0.053).
We also correlated Ki-67 expression with previous investigated markers [24–27], but no sig-
nificant correlation was found.
Univariate analyses. Significant variables, for the endpoints BF, CF and PCD are all pre-
sented in Table 1. For BF, significant prognostic factors were: pT-stage (p< 0.001), preopera-
tive PSA (p< 0.001), Gleason score (p< 0.001), tumor size (p< 0.001), perineural infiltration
(PNI, p< 0.001), non-apical PSM (p = 0.049), apical PSM (p< 0.001), vascular infiltration
(p< 0.001), and pN-stage (p< 0.001). For CF, significant prognostic factors were: pT-stage
(p< 0.001), Gleason score (p< 0.001), tumor size (p = 0.019), PNI (p = 0.001), non-apical
PSM (p< 0.001), vascular infiltration (p< 0.001) and pN-stage (p< 0.001). For PCD the signifi-
cant prognostic factors were: pT-stage (p = 0.027), Gleason score (p< 0.001), PNI (p = 0.002),
non-apical PSM (p = 0.029), vascular infiltration (p = 0.009) and pN-stage (p< 0.001). A high
Ki-67 expression ( 1.34) in tumor epithelium (digital scoring method) was significantly associ-
ated with BF, (p = 0.014, Fig 2A), but not with CF (p = 0.405) or PCD (p = 0.752). For visual
scoring with high cut-off value 1.43, high Ki-67 expression was significant with BF (p = 0.04),
but not with CF (p = 0.129) or PCD (p = 0.502). Stratification of the cohort into prognostic
groups according to the American Joint Committee on Cancer (AJCC) TNM system was imple-
mented [28]. Neither high- or low levels of Ki-67 was significant for any the staging groups; I
(n = 43), IIA (n = 111), IIB (219), III (n = 219) or IV (n = 3).
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Table 1. Patient characteristics clinicopathological variables and their prognostic variables for BF, CF and PCD (univariate analysis; log-rank











5-year EFS (%) p 10-year EFS (%) p 10-year EFS (%) p
Age 0.237 0.038 0.600
 65 years 357 67 76 92 97
> 65 years 178 33 70 88 96
pT-stage <0.001 <0.001 0.027
pT2 374 70 83 97 98
pT3a 114 21 61 87 98
pT3b 47 9 43 73 89
Preoperative PSA <0.001 0.029 0.061
PSA<10 308 57 81 95 99
PSA>10 221 42 68 89 95
Missing 6 1 - - -
ISUP grade group <0.001 <0.001 <0.001
1 (3+3) 183 34 83 98 99
2 (3+4) 219 41 77 94 98
3 (4+3) 81 15 70 90 95
4 (4+4) 17 4 58 86 94
5 (>8) 35 6 37 65 87
Tumor Size <0.001 0.019 0.098
0–20 mm 250 47 83 94 99
>20 mm 285 53 68 88 96
PNI <0.001 <0.001 0.002
No 401 75 80 96 98
Yes 134 25 60 83 93
PSM 0.049 0.198 0.697
No 249 47 81 96 97
Yes 286 53 69 90 97
Non-apical PSM <0.001 <0.001 0.029
No 381 71 82 96 98
Yes 154 29 57 85 94
Apical PSM 0.063 0.427 0.313
No 325 61 74 90 96
Yes 210 39 77 92 98
Vascular infiltration <0.001 <0.001 0.009
No 492 92 77 95 98
Yes 43 8 47 69 88
Nstage <0.001 <0.001 <0.001
Nx 264 49 79 96 99
N0 268 50 72 90 97
N1 3 1 0 33 67
Abbreviations: BF = biochemical failure; CF = clinical failure; EFS = event free survival in months; PCD = prostate cancer death; p = p value for log rank
statistics for difference in event free survival; PC = prostate cancer; PNI = perineural infiltration; PSA = prostate specific antigen; PSM = positive surgical
margin; Nstage = nodal status
https://doi.org/10.1371/journal.pone.0186852.t001
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Multivariate analyses. Results from the multivariate analysis are represented in Table 2
(digital scoring): pT-stage (p = 0.003), pT3a (p = 0.001, HR: 0.44, CI95% 0.27–0.82), ISUP
Fig 1. Representative immunohistochemical staining for Ki-67. (A) Gleason grade group 1 (3+3) with Ki-67 <1–2.5%; (B) Gleason
grade group 3 (4+3) with Ki-67 <1–2.5%; (C) Gleason grade group 3 (4+3) with Ki-67 2.6–4%; (D) Gleason grade group 4 (4+4) with Ki-
67 5; (E) Gleason grade group 5 (4–5) with Ki-67 2.6–4; (F) Picture showing the different Ki-67 expression of nuclear staining, varying from
negative to strong.
https://doi.org/10.1371/journal.pone.0186852.g001
High Ki67 levels predict biochemical failure in prostate cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0186852 November 15, 2017 6 / 13
Fig 2. Survival analysis for Ki-67 and mitotic count in primary tumors. (Kaplan-Meier method). Number
of events/number of cases are given in parenthesis. (A) Digital scoring; (B) Visual scoring.
https://doi.org/10.1371/journal.pone.0186852.g002
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grade group 2 (p = 0.028, HR: 0.52, CI95% 0.30–0.93), PNI (p = 0.040, HR: 1.70, CI95% 0.50–
0.98) and non-apical PSM (p = 0.002, HR: 0.60, CI95% 0.43–0.83) were independent prognos-
tic factors for BF. For CF, ISUP grade group 3 (p< 0.000), ISUP grade group 2 (< 0.000, HR:
0.08, CI95% 0.03–0.23); ISUP grade group 3 (p = 0.001, HR: 0.28 CI95% 0.13–0.58), ISUP
grade group 4 (p = 0.022, HR: 0.38 CI95% 0.17–0.87) and non-apical PSM (p = 0.041, HR:
0.60, CI95% 0.54–0.97). For PCD, ISUP grade group 2 (p = 0.033, HR: 0.11, CI95% 0.03–0.86),
ISUP grade group 3 (p = 0.035, HR:0.19, CI95% 0.04–0.89) and PNI (p = 0.027, HR: 0.30,
Table 2. Multivariate analyses (Cox regression, backward conditional) of Ki67 levels and significant clinicopathological variables. (n = 535). Digital
scoring method.






Age NS NS NS
 65 years 321
> 65 years 65
pT-stage 0.003 NS NS
pT2 333 1
pT3a 102 0.44 0.27–0.82 0.003
pT3b 40 0.70 0.44–1.12 0.140
Preoperative PSA NS NS NS
PSA <10 278
PSA >10 200
ISUP grade group 0.063 0.000 0.095
1 (3+3) 157 1 1 1
2 (3+4) 198 0.52 0.30–0.93 0.028 0.08 0.03–0.23 0.000 0.11 0.03–0.86 0.033
3 (4+3) 74 0.62 0.35–1.08 0.091 0.28 0.13–0.58 0.001 0.19 0.04–0.89 0.035
4 (4+4) 17 0.87 0.48–1.56 0.633 0.38 0.17–0.87 0.022 0.79 0.25–2.65 0.700
5 (>8) 32 1.02 0.46–2.26 0.956 0.44 0.12–1.54 0.199 0.61 0.07–5.31 0.651
Tumor size NS NS NS
0–20 mm 215
>20 mm 263
PNI 0.040 NS 0.027
No 401 1 1
Yes 134 0.70 0.50–0.98 0.30 0.11–0.87
Non-apical PSM 0.002 0.041 NS
No 381 1 1
Yes 154 0.60 0.43–0.83 0.54 0.30–0.97
Apical PSM NS NS NS
No 325
Yes 210
Vascular infiltration NS NS NS
No 437
Yes 41
Ki67 level NS NS NS
Low 289
High 189
Abbreviations: BF = biochemical failure; CF = clinical failure; PSA = prostate specific antigen; PNI = perineural infiltration, PSM = positive surgical margin;
NS = not significant.
https://doi.org/10.1371/journal.pone.0186852.t002
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CI95% 0.11–0.89–9). Ki-67 was not significant with none of the endpoints. Visual scoring is
presented in Table 3. For BF, pT-stage (p< 0.002), pT3a (p< 0.000, HR: 0.42, CI95% 0.26–
0.69), pT3b (p = 0.047, HR: 0.62, CI95% 0.39–0.99), preoperative PSA > 10ng/ml (p = 0.046,
HR: 0.68, CI95% 0.49–0.94), PNI (p< 0.008, HR: 0.62, CI95% 0.44–0.88), non-apical PSM
(p< 0.000, HR: 0.54, CI95% 0.39–0.77), apical PSM (p = 0.043, HR: 1.42, CI95% 1.01–2.00)
and Ki67 (p = 0.012, HR: 1.50, CI95% 1.10–2.06). For CF, ISUP grade group (p< 0.000),
grade group 2 (p< 0.000, HR: 0.07, CI95% 0.02–0.21), ISUP grade group 3 (p< 0.000, HR:
Table 3. Multivariate analyses (Cox regression, backward conditional) of Ki67 levels and significant clinicopathological variables. (n = 535). Visual
scoring method.






Age NS NS NS
 65 years 299
> 65 years 148
pT-stage 0.002 NS 0.090
pT2 307 1 1
pT3a 102 0.42 0.26–0.69 0.001 0.07 0.01–0.79 0.031
pT3b 38 0.62 0.39–0.99 0.047 0.11 0.01–0.96 0.046
Preoperative PSA 0.046 NS 0.034
PSA <10 255 1 1
PSA >10 192 0.62 0.49–0.94 0.25 0.07–0.90
ISUP grade group 0.077 0.000 0.161
1 (3+3) 139 1 1 1
2 (3+4) 190 0.00 0.00–0.47 0.023 0.07 0.02–0.21 0.000 0.17 0.03–0.98 0.047
3 (4+3) 71 0.02 0.00–0.54 0.020 0.25 0.12–0.51 0.000 0.13 0.04–0.91 0.037
4 (4+4) 16 0.03 0.00–0.78 0.035 0.34 0.15–1.30 0.015 0.66 0.18–2.33 0.513
5 (9) 31 0.18 0.23–1.11 0.065 0.37 0.11–1.30 0.121 0.59 0.07–5.17 0.631
Tumor size NS NS NS
0–20 mm 192
>20 mm 255
PNI 0.008 NS 0.005
No 332 1 1
Yes 115 0.62 0.44–0.88 0.19 0.05–0.66
Non-apical PSM 0.000 0.007
No 313 1 1
Yes 134 0.54 0.39–0.77 0.45 0.30–1.10
Apical PSM 0.034 NS NS
No 274 1
Yes 173 1.42 1.01–2.00
Vascular infiltration NS NS NS
No 408
Yes 39




High 175 1.50 1.10–1.26
Abbreviations: BF = biochemical failure; CF = clinical failure; PSA = prostate specific antigen; PNI = perineural infiltration, PSM = positive surgical margin;
NS = not significant.
https://doi.org/10.1371/journal.pone.0186852.t003
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0.25, CI95% 0.12–0.51), ISUP grade group 4 (p = 0.015, HR: 0.34, CI95% 0.15–1.30), non-api-
cal PSM (p = 0.007, HR: 0.45, CI95% 0.30–1.10). For PCD, PSA > 10ng/ml (p = 0.034, HR:
0.25, CI95% 0.07–0.90), ISUP grade group 2 (p = 0.047, HR: 0.17, CI95% 0.07–0.90) and ISUP
grade group 3 (p = 0.035, HR: 0.20, CI95% 0.04–0.91). Ki-67 was not significant with end-
points CF or PCD.
Discussion
Uncontrolled proliferation is a hallmark of malignancy and the measurement of Ki-67 antigen
by using IHC is the most widely performed assessment of a tumor’s proliferation potential. In
this large-scale multi-center study with long-term survival data, we found that a high expres-
sion of Ki-67 was an independent predictor for biochemical failure (both scoring methods). By
using visual scorings method, a high Ki-67 was found as an independent predictor for BF in
multivariate analyses. High expression of Ki-67 was strongly correlated to Gleason grade 8
and increased tumor size (> 20 mm). To the best of our knowledge, our study is one of the
largest series to explore the prognostic impact of mitotic count by using two different
methods.
Counting of mitoses is the classical method used to determine proliferative activity in nor-
mal and neoplastic tissues by using light microscopy. Despite that a lot of previous studies
have confirmed Ki-67 as a prognostic factor for PC [12–18, 29–31], Ki-67 count has not been
implemented in PC is not implemented in PC diagnosis. One of the main reason for this,
includes, the morphologic heterogeneity of PC, as these methods only registers the M phase of
the cell cycle [2–3] while, the number of identifiable mitoses may also depend upon the period
of time between surgical removal and fixation of the specimen [32], Furthermore, there are
several available antibodies or Ki-67 IHC staining, but there is no standard operating protocol,
and the cut-off definition values for Ki-67 levels have not been established [33]. Moreover, the
biological heterogeneity of Ki67 staining can occur across prostate cancer specimens, and defi-
nition of the location and extent of the area of the cancer that should be scored is controversial
needs to be more clearly defined. This has the main important reason of the low interobserver
reproducibility. Importantly, most studies are retrospectively designed with various number of
patients included [12–18] which may explain the poor reproducibility of mitotic counts.
However, a significant association have been found between Ki-67 antigen expression and
time to progression, high Gleason grade, large tumor size, metastasis, mortality and to predict
distant metastases in men treated with radiotherapy and androgen deprivation [12, 13, 17, 18,
29–31, 34]. We did not find any association between Ki-67 and CF and PCD. This is most
likely due with the low number of events for CF and PCD in our cohort. In two published PC
studies measuring proliferating by using MIB-1 the investigators were not able to find signifi-
cant association with PC and Ki-67 expression [15, 16].
Immunostaining for Ki-67 (IHC), is relatively straightforward. By means of immunostain-
ing it is possible to assess the growth fraction of neoplastic cell populations. In this study, we
used the anti-Ki-67 (clone:30–9) antibody which is a rabbit monoclonal primary antibody
from Ventana. This antibody is intended for use to identify stained proliferating cells by light
microscopy in sections of formalin fixed, paraffin embedded tissue. However, in practice, the
monoclonal antibody MIB-1 is probably the most widely used proliferative marker. It reacts
with an antigen that is only present in the nucleus of proliferating cells and has similar epitope
sensitivity to Ki-67. There have been many reports of correlations between Ki-67 equivalent
antibodies and other proliferation markers [35, 36]. The antibody used in this study is in daily
use in our pathology department to assess the proliferative activity of normal and neoplastic
cells. A study by Leonardo et al. [37] concluded that as a rabbit monoclonal antibody
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(RbMAb), it demonstrates increased sensitivity and strong specificity compared with mouse
monoclonal antibodies (MMAbs). With intense nuclear staining and no adipose (K2) or cell
membrane staining (MIB-1), CONFIRM Ki-67 (30–9) rabbit monoclonal antibody can be
used in assessment of tumor aggressiveness [37].
Determination of proliferative activity by the use of Ki-67 depends on several factors, the
most obvious being the interobserver variation. In our study, we used the same cut-off values
and TMA-slides for both visual and digital analyses, and observed, in fact, a good ICC between
the two investigators. At the other hand, the interpretation is not straightforward.
In the present study, we used two different approaches to measure Ki-67 expression, by
visual and digital scoring. There was high inter-correlation agreement between the pathologist
visual scoring and the pathologist digital scoring. This is in agreement with one similar study
(no = 225) [37]. Limitations of our study include its retrospective nature as well as the use of
TMA cores and not whole slide sections to determine the proliferative activity. Although the
use of TMA may result in a bias, due to the heterogeneity of PC. A more representative
method, at least with respect to Ki-67, could be better achieved with multiple cores taken from
each single lesion. Another limitation might be the antibody used. Nevertheless, international
standardisation of analysis and assessment of any potential biomarker is an important aspect
for a successful translation into the routine setting [38].
In conclusion, Ki-67 is a biomarker for tumor cell proliferation. In our study, we found that
a high Ki-67 expression was an independent prognostic marker for biochemical failure, high
Gleason grade and larger tumor size. Despite unresolved issues on Ki-67 value cut-offs, we sug-
gest that the analysis of Ki-67 add information regarding the aggressiveness of prostate tumors.
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5. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a
prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer
registry. Breast Cancer Res Treat. 2013; 139(2): 539–552. https://doi.org/10.1007/s10549-013-2560-8
PMID: 23674192
6. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, et al. Extranodal NK/T-cell lymphoma, nasal type: a report of
73 cases at MD Anderson Cancer Center. Am J Surg Pathol. 2013; 37 (1): 14–23. https://doi.org/10.
1097/PAS.0b013e31826731b5 PMID: 23232851
7. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
Pathol Oncol Res. 2006; 12: 143–147. PMID: 16998593
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